A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs DAS 181 (Primary)
- Indications Parainfluenza virus infections
- Focus Therapeutic Use
- Sponsors Ansun Biopharma
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 02 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.